Loading...
Publication
Os Potenciais Efeitos Antidepressivos Da Cetamina Em Animais De Companhia
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 763.05 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
A cetamina é uma substância ativa presente em alguns medicamentos aprovados e utilizados na indução de anestesia geral desde os anos 1970. Desde cedo se percebeu que doentes operados sob o efeito de cetamina apresentavam frequentemente, ao acordar, um quadro transitório de manifestações psicológicas atípicas, com potencial interesse terapêutico no campo da saúde mental. Durante a sua aplicação, a cetamina induz modificações do estado de consciência com muitas semelhanças com aquelas induzidas por psicadélicos clássicos, apesar de existirem algumas diferenças, pelo que é amplamente considerada pela comunidade científica internacional como um psicadélico atípico.
Sobretudo ao longo das últimas duas décadas, a cetamina tem sido investigada como um potencial tratamento farmacológico inovador, com eficácia e segurança demonstradas em seres humanos diagnosticados com depressão refratária. No panorama internacional, constitui uma opção terapêutica descrita nos principais livros de psicofarmacologia, apesar da evidência científica produzida ainda não ter sido suficiente para gerar aprovação pelas entidades reguladoras.
Vários ensaios clínicos realizados em modelos animais submetidos a condições de stresse relataram diminuições significativas e sustentadas dos estados depressivos e/ou de stresse num número elevado destes animais, após uma única administração de cetamina, que perduraram no máximo até 28 dias.
Com o presente trabalho pretende-se analisar alguns dados recentemente publicados acerca dos ensaios clínicos realizados em modelos animais com cetamina como antidepressivo e avaliar os seus potenciais usos e efeitos em animais de companhia.
Ketamine is an active substance present in some approved medications and used in the induction of general anesthesia since the 1970s. It was soon noticed that patients operated under the influence of ketamine often presented, upon awakening, a transitory picture of atypical psychological manifestations, with potential therapeutic interest in the field of mental health. Once administered, ketamine induces changes in the state of consciousness with many similarities to those induced by classic psychedelics, although there are some differences, which is why it is widely considered by the international scientific community as an atypical psychedelic. Especially over the last two decades, ketamine has been investigated as a potential innovative pharmacological treatment, with demonstrated efficacy and safety in humans diagnosed with refractory depression. In the international landscape, it constitutes a therapeutic option described in the main psychopharmacology books, despite the produced scientific evidence having not yet been sufficient to generate approval by regulatory authorities. Several clinical trials conducted in animal models subjected to stressful conditions reported significant and sustained decreases in depressive and/or stressful states in a large amount of these animals, after a single administration of ketamine, which lasted a maximum of 28 days. The present paper aims to analyze some recently published data on clinical trials carried out with ketamine as an antidepressant in animal models and evaluate its potential uses and effects in companion animals.
Ketamine is an active substance present in some approved medications and used in the induction of general anesthesia since the 1970s. It was soon noticed that patients operated under the influence of ketamine often presented, upon awakening, a transitory picture of atypical psychological manifestations, with potential therapeutic interest in the field of mental health. Once administered, ketamine induces changes in the state of consciousness with many similarities to those induced by classic psychedelics, although there are some differences, which is why it is widely considered by the international scientific community as an atypical psychedelic. Especially over the last two decades, ketamine has been investigated as a potential innovative pharmacological treatment, with demonstrated efficacy and safety in humans diagnosed with refractory depression. In the international landscape, it constitutes a therapeutic option described in the main psychopharmacology books, despite the produced scientific evidence having not yet been sufficient to generate approval by regulatory authorities. Several clinical trials conducted in animal models subjected to stressful conditions reported significant and sustained decreases in depressive and/or stressful states in a large amount of these animals, after a single administration of ketamine, which lasted a maximum of 28 days. The present paper aims to analyze some recently published data on clinical trials carried out with ketamine as an antidepressant in animal models and evaluate its potential uses and effects in companion animals.
Description
Keywords
Antidepressivo Cetamina Depressão Psicadélico Stresse Antidepressant Depression Ketamine Psychedelic Stress